Cargando…

Risk of Infection Associated With Subsequent Biologic Agent Use After Rituximab: Results From a National Rheumatoid Arthritis Patient Registry

OBJECTIVE: To assess whether the time between the last rituximab infusion and initiation of a different biologic agent influenced infection risk in patients with rheumatoid arthritis (RA). METHODS: Patients with RA who newly initiated rituximab within the Consortium of Rheumatology Researchers of No...

Descripción completa

Detalles Bibliográficos
Autores principales:	Harrold, Leslie R., Reed, George W., Karki, Chitra, Magner, Robert, Shewade, Ashwini, John, Ani, Kremer, Joel M., Greenberg, Jeffrey D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Brief Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5132134/ https://www.ncbi.nlm.nih.gov/pubmed/27111064 http://dx.doi.org/10.1002/acr.22912

Ejemplares similares

Comparative effectiveness and safety of rituximab versus subsequent anti–tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti–tumor necrosis factor therapies in the United States Corrona registry
por: Harrold, Leslie R., et al.
Publicado: (2015)

Impact of rituximab on patient-reported outcomes in patients with rheumatoid arthritis from the US Corrona Registry
por: Harrold, Leslie R., et al.
Publicado: (2017)

Characteristics Associated with Biologic Monotherapy Use in Biologic-Naive Patients with Rheumatoid Arthritis in a US Registry Population
por: Pappas, Dimitrios A., et al.
Publicado: (2015)

Impact of Tocilizumab Monotherapy on Clinical and Patient-Reported Quality-of-Life Outcomes in Patients with Rheumatoid Arthritis
por: Harrold, Leslie R., et al.
Publicado: (2017)

Disease activity and biologic use in patients with psoriatic arthritis or rheumatoid arthritis
por: Kavanaugh, Arthur, et al.
Publicado: (2018)

Long-Term Effectiveness of Adalimumab in Patients with Rheumatoid Arthritis: An Observational Analysis from the Corrona Rheumatoid Arthritis Registry
por: Pappas, Dimitrios A., et al.
Publicado: (2017)

Prevalence of Sjögren’s syndrome associated with rheumatoid arthritis in the USA: an observational study from the Corrona registry
por: Harrold, Leslie R., et al.
Publicado: (2020)

Malignancy validation in a United States registry of rheumatoid arthritis patients
por: Fisher, Mark C, et al.
Publicado: (2012)

Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry
por: Harrold, Leslie R., et al.
Publicado: (2016)

Cluster‐Randomized Trial of a Behavioral Intervention to Incorporate a Treat‐to‐Target Approach to Care of US Patients With Rheumatoid Arthritis
por: Harrold, Leslie R., et al.
Publicado: (2018)

Discontinuation of Biologic Therapy in Rheumatoid Arthritis: Analysis from the Corrona RA Registry
por: Strand, Vibeke, et al.
Publicado: (2017)

The rheumatoid arthritis treat-to-target trial: a cluster randomized trial within the Corrona rheumatology network
por: Harrold, Leslie R, et al.
Publicado: (2014)

Immunosuppressive treatment and the risk of diabetes in rheumatoid arthritis
por: Lillegraven, Siri, et al.
Publicado: (2019)

Real-world Comparative Effectiveness of Tocilizumab Monotherapy vs. Tumor Necrosis Factor Inhibitors with Methotrexate in Patients with Rheumatoid Arthritis
por: Harrold, Leslie R., et al.
Publicado: (2018)

The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor
por: Harrold, Leslie R, et al.
Publicado: (2015)

Time‐Varying Association of Rheumatoid Arthritis Disease Activity to Subsequent Cardiovascular Risk
por: Yoshida, Kazuki, et al.
Publicado: (2022)

Disease activity and patient-reported outcomes in patients with rheumatoid arthritis and Sjögren’s syndrome enrolled in a large observational US registry
por: Harrold, Leslie R., et al.
Publicado: (2020)

Rituximab for Rheumatoid Arthritis
por: Cohen, Marc D., et al.
Publicado: (2015)

“Design characteristics of the CORRONA CERTAIN study: a comparative effectiveness study of biologic agents for rheumatoid arthritis patients”
por: Pappas, Dimitrios A, et al.
Publicado: (2014)

Comparative Effectiveness of Abatacept Versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis Who Are Anti-CCP Positive in the United States Corrona Registry
por: Harrold, Leslie R., et al.
Publicado: (2019)

Identifying factors associated with concordance with the American College of Rheumatology rheumatoid arthritis treatment recommendations
por: Harrold, Leslie R., et al.
Publicado: (2016)

A Model to Predict Future Biologic or Targeted Synthetic DMARD Switch at a Subsequent Clinic Visit in Rheumatoid Arthritis
por: Cappelli, Laura C., et al.
Publicado: (2023)

Safety of biologic agents after rituximab therapy in patients with rheumatoid arthritis
por: Mishra, Richa, et al.
Publicado: (2009)

One-year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: data from a national U.S. rheumatoid arthritis registry
por: Harrold, Leslie R., et al.
Publicado: (2018)

Rituximab for the treatment of rheumatoid arthritis: an update
por: Mok, Chi Chiu
Publicado: (2013)

Durability of Response to Tocilizumab Therapy in Rheumatoid Arthritis: Data from the US-Based Corrona Rheumatoid Arthritis Registry
por: Pappas, Dimitrios A., et al.
Publicado: (2021)

The Belgian MIRA (MabThera In Rheumatoid Arthritis) registry: clues for the optimization of rituximab treatment strategies
por: Vander Cruyssen, Bert, et al.
Publicado: (2010)

Patient Perception of Cardiovascular Risk in Rheumatoid Arthritis
por: Banerjee, Shubhasree, et al.
Publicado: (2020)

Delays in Initiation of Disease-Modifying Therapy in Rheumatoid Arthritis Patients: Data from a US-Based Registry
por: Pappas, Dimitrios A., et al.
Publicado: (2015)

Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: data from the AutoImmunity and Rituximab registry
por: Salmon, J H, et al.
Publicado: (2015)

Rituximab and its potential for the treatment of rheumatoid arthritis
por: Bryant, Adam, et al.
Publicado: (2006)

Targeted therapies in rheumatoid arthritis: Focus on rituximab
por: Teng, YKO, et al.
Publicado: (2007)

Rituximab therapy in Greek patients with rheumatoid arthritis
por: Tsiakalos, Aristotelis P, et al.
Publicado: (2008)

Seronegative and seropositive rheumatoid arthritis treated with rituximab
por: Velloso Feijoo, Maria Luisa, et al.
Publicado: (2012)

Update on the use of rituximab for intractable rheumatoid arthritis
por: Looney, R John
Publicado: (2009)

Clinical and demographic factors associated with change and maintenance of disease severity in a large registry of patients with rheumatoid arthritis
por: Reed, George W., et al.
Publicado: (2017)

Baseline patient characteristics associated with response to biologic therapy in patients with psoriatic arthritis enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
por: Mease, Philip J, et al.
Publicado: (2018)

Repeated B-cell depletion with rituximab in rheumatoid arthritis
por: Edwards, J, et al.
Publicado: (2003)

Rituximab treatment in rheumatoid arthritis: how does it work?
por: Boumans, Maria JH, et al.
Publicado: (2009)

Treatment of Rheumatoid Arthritis with Biologic DMARDS (Rituximab and Etanercept)
por: Gashi, Afrim A., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_cum38omt984rslu43bk5s3dbfl